scholarly journals CLINICAL EFFICACY OF RAJAH PRAVARTINI VATI IN THE MANAGEMENT OF ARTAVA KSHAYA (OLIGOMENORRHOEA)

2020 ◽  
Vol p4 (06) ◽  
pp. 2480-2485
Author(s):  
Chauhan Monika ◽  
Makeem Rita
Keyword(s):  
Clinical Trial ◽  
Blood Flow ◽  
Heart Disease ◽  
Clinical Study ◽  
Clinical Efficacy ◽  
Clinical Assessment ◽  
Side Effect ◽  
Endocrine Disorders

A clinical trial was carried out on 30 oligomenorrhoea [ArtavaKshaya] patients aged between 18 to 35 years having complaints of irregular, scanty and painful menstruations. The patients were registered from OPD and IPD of Patanjali Ayurveda College, Haridwar. They were administrated Rajahpravartini Vati for three months in a dose of 250mg twice daily. The specific investigations were done in order to exclude TB endometritis, endocrine disorders, diabetes and heart disease. The clinical assessment was carried out in thirty days intervals. It is inferred that the study discloses the effect of Rajahpravartini Vati on irregularity of interval of menstruation [90.47%], duration of menstruation [79.37%], amount of blood flow [90.00%] and pain during menstruation [100.00%] which were highly significant in clinical study. No untoward side effect was noticed during clinical trial.

Metabolic and hormonal blood flow modeling in patients with coronary heart disease: In vitro and clinical study

2007 ◽  
Vol 22 (3) ◽  
pp. 173-184 ◽  
Author(s):  
Lidia I. Malinova ◽  
Georgy V. Simonenko ◽  
Tatyana P. Denisova ◽  
Valery V. Tuchin
Keyword(s):  
Coronary Heart Disease ◽  
Blood Flow ◽  
Heart Disease ◽  
Clinical Study ◽  
Flow Modeling ◽  
Blood Flow Modeling

scholarly journals Comparative Clinical Efficacy of Guduchyadi Syrup and Guduchyadi Ghanvati in Management of Amlapitta

2020 ◽  
Vol 11 (2) ◽  
pp. 261-264
Author(s):  
Urvee N Solanki ◽  
Darshan K Parmar
Keyword(s):  
Clinical Trial ◽  
Clinical Efficacy ◽  
Clinical Assessment ◽  
Dosage Form ◽  
Similar Efficacy ◽  
Dosage Forms ◽  
Yoga Group ◽  
Group A ◽  
Group B

Introduction: Amalpitta is most common problem nowadays. Guduchyadi yoga kwatha was indicated in classics in the management of Amlapitta. Kwatha is very effective but it is unpleasant to some patients. So the kwatha was converted into preferable dosage form as requirement of present era. Material and Method: A Clinical trial was carried out on 60 Patients of Amlapitta aged 20 to 60 years with complaints of Aruchi, Avipaka, Tiktodgar, Amlodgar, Urodaha, Kanthadaha etc., who were registered from OPD of Government Ayurved Hospital, Vadodara. They were equally divided into two groups  i.e. Group A- Guduchyadi Syrup given in 20ml BD dose and Group B- Guduchyadi Ghanavati given at 500mg2 BD ). Each group was treated for 28 days administered empty stomach. The clinical assessment was carried out on the 28th  day and  2 weeks after the 28 days of treatment (after follow up period) for the  objective & subjective parameters and it was seen that both the dosage form Guduchyadi Syrup and Guduchyadi Ghanavati were very effective and cured or markedly relieved the symptoms of Amlapitta. Results: The study shows the effect of Guduchyadi Syrup and Guduchyadi Ghanavati, which led to cure in 16 patients (53.33%) and 22(73.33%) patients respectively, and markedly improvement in 12(40%) and 8(26.67%) patients affected with Amlapitta disease respectively. Conclusion: Both trial dosage forms of Guduchyadi Yoga, (Group A- Syrup & Group B- Ghanavati )  relieved the symptoms of Amlapitta and both the formulation have comparatively similar efficacy in the management of Amlapitta.

Integration Between Computed Tomography and Nuclear Medicine for Non-invasive Assessment of Coronary Anatomy and Myocardial Perfusion

2009 ◽  
Vol 5 (2) ◽  
pp. 15
Author(s):  
Wanda Acampa ◽  
Mario Petretta ◽  
Carmela Nappi ◽  
Alberto Cuocolo ◽  
◽  
...  
Keyword(s):  
Computed Tomography ◽  
Coronary Heart Disease ◽  
Blood Flow ◽  
Heart Disease ◽  
Myocardial Perfusion ◽  
Myocardial Blood Flow ◽  
Imaging Techniques ◽  
Emission Computed Tomography ◽  
Coronary Anatomy ◽  
Non Invasive

Many non-invasive imaging techniques are available for the evaluation of patients with known or suspected coronary heart disease. Among these, computed-tomography-based techniques allow the quantification of coronary atherosclerotic calcium and non-invasive imaging of coronary arteries, whereas nuclear cardiology is the most widely used non-invasive approach for the assessment of myocardial perfusion. The available single-photon-emission computed tomography flow agents are characterised by a cardiac uptake proportional to myocardial blood flow. In addition, different positron emission tomography tracers may be used for the quantitative measurement of myocardial blood flow and coronary flow reserve. Extensive research is being performed in the development of non-invasive coronary angiography and myocardial perfusion imaging using cardiac magnetic resonance. Finally, new multimodality imaging systems have recently been developed bringing together anatomical and functional information. This article provides a description of the available non-invasive imaging techniques in the assessment of coronary anatomy and myocardial perfusion in patients with known or suspected coronary heart disease.

Cerebrovascular Blood Flow Dynamic Changes in Fetuses with Congenital Heart Disease

2009 ◽  
Vol 25 (1) ◽  
pp. 167-172 ◽  
Author(s):  
Lv Guorong ◽  
Li Shaohui ◽  
Jin Peng ◽  
Lin Huitong ◽  
Li Boyi ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Blood Flow ◽  
Heart Disease ◽  
Congenital Heart ◽  
Flow Dynamic ◽  
Dynamic Changes ◽  
Blood Flow Dynamic

scholarly journals Lifestyle and Treatment Adherence Intervention after a Coronary Event Based on an Interactive Web Application (EVITE): Randomized Controlled Clinical Trial Protocol

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1818
Author(s):  
MªÁngeles Bernal-Jiménez ◽  
Germán Calle-Pérez ◽  
Alejandro Gutiérrez-Barrios ◽  
Livia Gheorghe ◽  
Ana María Solano-Mulero ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Treatment Adherence ◽  
Coronary Event ◽  
Mobile Telephone ◽  
Analysis Of Covariance ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Randomized Controlled

Coronary heart disease is one of the main causes of morbimortality around the world. Patients that survive a coronary event suffer a high risk of readmission, relapse and mortality, attributed to the sub-optimal control of cardiovascular risk factors (CVRF), which highlights the need to improve secondary prevention strategies aimed at improving their lifestyle and adherence to treatment. Through a randomized controlled clinical trial, this study aims to evaluate the effect of an intervention involving an online health application supported by a mobile telephone or tablet (mHealth) on lifestyle (diet, physical activity, and tobacco consumption) and treatment adherence among people with coronary heart disease after percutaneous coronary intervention. The sample will comprise 240 subjects (120 in each arm: intervention and usual care). They are assessed immediately and nine months after their hospital discharge about sociodemographic, clinical, CVRF, lifestyle, and treatment adherence characteristics. The educative intervention, involving a follow-up and self-monitoring, will be performed using an online mHealth tool consisting of an application for mobile phones and tablets. The quantitative primary outcomes from the two groups will be compared using an analysis of covariance (ANCOVA) adjusted for age and gender. A multivariate analysis will be performed to examine the association of the intervention with lifestyle habits, the control of CVRFs, and outcomes after discharge in terms of the use of health services, emergency visits, cardiovascular events and readmissions.

scholarly journals Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications—a methodological review

BMC Medicine ◽  
2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Asger S. Paludan-Müller ◽  
Perrine Créquit ◽  
Isabelle Boutron
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Clinical Study ◽  
Primary Source ◽  
European Medicines Agency ◽  
Clinical Trial Registries ◽  
Number Of Patients ◽  
Journal Publications ◽  
Clinical Study Reports ◽  
Completeness Of Reporting

Abstract Background An accurate and comprehensive assessment of harms is a fundamental part of an accurate weighing of benefits and harms of an intervention when making treatment decisions; however, harms are known to be underreported in journal publications. Therefore, we sought to compare the completeness of reporting of harm data, discrepancies in harm data reported, and the delay to access results of oncological clinical trials between three sources: clinical study reports (CSRs), clinical trial registries and journal publications. Methods We used the EMA clinical data website to identify all trials submitted to the EMA between 2015 and 2018. We retrieved all CSRs and included all phase II, II/III or III randomised controlled trials (RCTs) assessing targeted therapy and immunotherapy for cancer. We then identified related records in clinical trial registries and journals. We extracted harms data for eight pre-specified variables and determined the completeness of reporting of harm data in each of the three sources. Results We identified 42 RCTs evaluating 13 different drugs. Results were available on the EMA website in CSRs for 37 (88%) RCTs, ClinicalTrials.gov for 36 (86%), the European Clinical Trials Register (EUCTR) for 20 (48%) and in journal publications for 32 (76%). Harms reporting was more complete in CSRs than other sources. We identified marked discrepancies in harms data between sources, e.g. the number of patients discontinuing due to adverse events differed in CSRs and clinical trial registers for 88% of trials with data in both sources. For CSRs and publications, the corresponding number was 90%. The median (interquartile range) delay between the primary trial completion date and access to results was 4.34 (3.09–7.22) years for CSRs, 2.94 (1.16–4.52) years for ClinicalTrials.gov, 5.39 (4.18–7.33) years for EUCTR and 2.15 (0.64–5.04) years for publications. Conclusions Harms of recently approved oncological drugs were reported more frequently and in more detail in CSRs than in trial registries and journal publications. Systematic reviews seeking to address harms of oncological treatments should ideally use CSRs as the primary source of data; however, due to problems with access, this is currently not feasible.

scholarly journals Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris

2013 ◽  
Vol 5 ◽  
pp. CMT.S7824 ◽  
Author(s):  
Mohammed Aldakkak ◽  
David F. Stowe ◽  
Amadou K.S. Camara
Keyword(s):  
Coronary Heart Disease ◽  
Blood Flow ◽  
Heart Disease ◽  
Supply And Demand ◽  
Chronic Stable Angina ◽  
The United States ◽  
Lifestyle Changes ◽  
Channel Blockers ◽  
Coronary Syndrome ◽  
Chronic Angina

Coronary heart disease is a global malady and it is the leading cause of death in the United States. Chronic stable angina is the most common manifestation of coronary heart disease and it results from the imbalance between myocardial oxygen supply and demand due to reduction in coronary blood flow. Therefore, in addition to lifestyle changes, commonly used pharmaceutical treatments for angina (nitrates, β-blockers, Ca2+ channel blockers) are aimed at increasing blood flow or decreasing O2 demand. However, patients may continue to experience symptoms of angina. Ranolazine is a relatively new drug with anti-anginal and anti-arrhythmic effects. Its anti-anginal mechanism is not clearly understood but the general consensus is that ranolazine brings about its anti-anginal effects by inhibiting the late Na+ current and the subsequent intracellular Ca2+ accumulation. Recent studies suggest other effects of ranolazine that may explain its anti-anginal and anti-arrhythmic effects. Nonetheless, clinical trials have proven the efficacy of ranolazine in treating chronic angina. It has been shown to be ineffective, however, in treating acute coronary syndrome patients. Ranolazine is a safe drug with minimal side effects. It is metabolized mainly in the liver and cleared by the kidney. Therefore, caution must be taken in patients with impaired hepatic or renal function. Due to its efficacy and safety, ranolazine was approved for the treatment of chronic angina by the Food and Drug Administration (FDA) in 2006.

Sign in / Sign up

Export Citation Format

Share Document